ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SGEN Seagen Inc

228.74
0.00 (0.00%)
Pre Market
Last Updated: 18:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 228.74
Ask Price 228.74
News -
Day High

Low
169.13

52 Week Range

High
228.96

Day Low
Share Name Share Symbol Market Stock Type
Seagen Inc SGEN NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 228.74 18:00:00
Open Price Low Price High Price Close Price Previous Close
228.74
Trades Shares Traded Average Volume 52 Week Range
0 0 - 169.13 - 228.96
Last Trade Type Quantity Price Currency
- 0 US$ 228.74 USD

Seagen Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
US$ 43.15B - - - -7,093.76
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Seagen News

Date Time Source News Article
1/09/202405:12IH Market NewsWall Street Highlights: HPE and Juniper Networks in..
12/26/202305:12Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section..
12/18/202317:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
12/18/202316:25Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of..
12/15/202317:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
12/15/202317:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
12/15/202317:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
12/15/202317:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
12/15/202317:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
12/15/202317:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
12/15/202317:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
12/15/202317:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No SGEN Message Board. Create One! See More Posts on SGEN Message Board See More Message Board Posts

Historical SGEN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months212.72228.96212.525226.645,062,09716.027.53%
6 Months209.00228.96203.605216.291,823,70719.749.44%
1 Year182.54228.96169.13204.481,552,64746.2025.31%
3 Years151.79228.96105.43169.681,159,19476.9550.70%
5 Years72.34228.9662.90152.861,107,057156.40216.20%

Seagen Description

Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com